Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MLH1 Loss in Primary Prostate Cancer.
Nourmohammadi Abadchi S, Sena LA, Antonarakis ES, Pritchard CC, Eshleman JR, Konnick EQ, Salipante SJ, Shenderov E, Lotan TL. Nourmohammadi Abadchi S, et al. Among authors: sena la. JCO Precis Oncol. 2023 May;7:e2200611. doi: 10.1200/PO.22.00611. JCO Precis Oncol. 2023. PMID: 37196219 Free PMC article.
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
Sena LA, Fountain J, Isaacsson Velho P, Lim SJ, Wang H, Nizialek E, Rathi N, Nussenzveig R, Maughan BL, Velez MG, Ashkar R, Larson AC, Pritchard CC, Adra N, Bryce AH, Agarwal N, Pardoll DM, Eshleman JR, Lotan TL, Antonarakis ES. Sena LA, et al. Oncologist. 2021 Feb;26(2):e270-e278. doi: 10.1002/onco.13601. Epub 2020 Dec 3. Oncologist. 2021. PMID: 33215787 Free PMC article.
Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy.
Sena LA, Wang H, Lim ScM SJ, Rifkind I, Ngomba N, Isaacs JT, Luo J, Pratz C, Sinibaldi V, Carducci MA, Paller CJ, Eisenberger MA, Markowski MC, Antonarakis ES, Denmeade SR. Sena LA, et al. Eur J Cancer. 2021 Feb;144:302-309. doi: 10.1016/j.ejca.2020.11.043. Epub 2020 Dec 29. Eur J Cancer. 2021. PMID: 33383350 Free PMC article. Clinical Trial.
Targeting the spectrum of immune checkpoints in prostate cancer.
Sena LA, Denmeade SR, Antonarakis ES. Sena LA, et al. Expert Rev Clin Pharmacol. 2021 Oct;14(10):1253-1266. doi: 10.1080/17512433.2021.1949287. Epub 2021 Jul 15. Expert Rev Clin Pharmacol. 2021. PMID: 34263692 Free PMC article. Review.
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
Markowski MC, Taplin ME, Aggarwal R, Sena LA, Wang H, Qi H, Lalji A, Sinibaldi V, Carducci MA, Paller CJ, Marshall CH, Eisenberger MA, Sanin DE, Yegnasubramanian S, Gomes-Alexandre C, Ozbek B, Jones T, De Marzo AM, Denmeade SR, Antonarakis ES. Markowski MC, et al. Among authors: sena la. Nat Commun. 2024 Jan 2;15(1):14. doi: 10.1038/s41467-023-44514-2. Nat Commun. 2024. PMID: 38167882 Free PMC article. Clinical Trial.
Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer.
Bergom HE, Sena LA, Day A, Miller B, Miller CD, Lozada JR, Zorko N, Wang J, Shenderov E, Lobo FP, Caramella-Pereira F, Marchionni L, Drake CG, Lotan T, De Marzo AM, Hwang J, Antonarakis ES. Bergom HE, et al. Among authors: sena la. NPJ Genom Med. 2024 Jan 22;9(1):7. doi: 10.1038/s41525-024-00392-1. NPJ Genom Med. 2024. PMID: 38253539 Free PMC article.
42 results